---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Nivolumab and Relatlimab-rmbw - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab-and-relatlimab-rmbw
version: v1
---

# Nivolumab and Relatlimab-rmbw - NCI

# Nivolumab and Relatlimab-rmbw

Placeholder slot

(nih-VOL-yoo-mab … reh-LAT-lih-mab)

This page contains brief information about nivolumab and relatlimab-rmbw
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Opdualag

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b22c9d83-3256-4e17-85f7-f331a504adc6&audience=consumer)

## Use in Cancer

Nivolumab and relatlimab-rmbw
is approved to treat:

- **[Melanoma](/Common/PopUps/popDefinition.aspx?id=45135&version=Patient&language=English)** that is [metastatic](/Common/PopUps/popDefinition.aspx?id=44058&version=Patient&language=English) or cannot be removed by [surgery](/Common/PopUps/popDefinition.aspx?id=45570&version=Patient&language=English). It is used in adults and children aged 12 years and older.

Nivolumab and relatlimab-rmbw is a combination form of [nivolumab](/Common/PopUps/popDefinition.aspx?id=767747&version=Patient&language=English) and relatlimab. This form may work better than either drug alone. For more information about nivolumab that may apply to this combination drug, see the Drug Information Summary for [Nivolumab](/about-cancer/treatment/drugs/nivolumab).

Nivolumab and relatlimab-rmbw
is also being studied in the treatment of other types of
[cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=Patient&language=English).

## More About Nivolumab and Relatlimab-rmbw

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/809169) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Nivolumab and Relatlimab-rmbw](https://medlineplus.gov/druginfo/meds/a622037.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects](https://www.cancer.gov/news-events/cancer-currents-blog/2022/immunotherapy-myocarditis-cause)

[Targeted Cancer Therapies](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3](https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-opdualag-melanoma-lag-3)

[Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma](https://www.cancer.gov/news-events/cancer-currents-blog/2021/melanoma-nivolumab-relatlimab-immunotherapy)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

[Immune Checkpoint Inhibitors](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Nivolumab/relatlimab-rmbw](https://www.cancer.gov/research/participate/clinical-trials/intervention/C186440) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
